Universidad Peruana Cayetano Heredia
Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair
JavaScript is disabled for your browser. Some features of this site may not work without it.
Mostrar el registro sencillo del ítem
| dc.contributor.author | Salazar, C.A. | |
| dc.contributor.author | Málaga Rodríguez, Germán Javier | |
| dc.contributor.author | Malasquez, G. | |
| dc.contributor.author | Bernardo, R. | |
| dc.date.accessioned | 2019-02-22T14:56:09Z | |
| dc.date.available | 2019-02-22T14:56:09Z | |
| dc.date.issued | 2015 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12866/5848 | |
| dc.description.abstract | This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To examine the existing clinical evidence on the efficacy of prophylactic anticoagulation with direct factor Xa inhibitors versus low molecular weight heparins in the prevention of venous thromboembolism in patients who have undergone total hip or knee replacement or hip fracture repair. To examine the existing clinical evidence on the efficacy of prophylactic anticoagulation with direct factor Xa inhibitors versus vitamin K antagonists, in the prevention of venous thromboembolism in patients who have undergone total hip or knee replacement or hip fracture repair. To evaluate the existing clinical evidence on the risks including any adverse event (serious or not) of bleeding, skin necrosis, heparin‐induced thrombocytopenia or hepatopathy associated with the analyzed therapies, in the prevention of venous thromboembolism in patients who have undergone total hip or knee replacement or hip fracture repair. | en_US |
| dc.language.iso | eng | |
| dc.publisher | Wiley | |
| dc.relation.ispartofseries | Cochrane Database of Systematic Reviews | |
| dc.rights | info:eu-repo/semantics/restrictedAccess | |
| dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es | |
| dc.subject | human | en_US |
| dc.subject | Article | en_US |
| dc.subject | chemoprophylaxis | en_US |
| dc.subject | priority journal | en_US |
| dc.subject | drug efficacy | en_US |
| dc.subject | bleeding | en_US |
| dc.subject | venous thromboembolism | en_US |
| dc.subject | anticoagulant therapy | en_US |
| dc.subject | warfarin | en_US |
| dc.subject | adverse event | en_US |
| dc.subject | antivitamin K | en_US |
| dc.subject | blood clotting factor 10a inhibitor | en_US |
| dc.subject | elective surgery | en_US |
| dc.subject | fondaparinux | en_US |
| dc.subject | fracture treatment | en_US |
| dc.subject | heparin induced thrombocytopenia | en_US |
| dc.subject | hip fracture | en_US |
| dc.subject | hip replacement | en_US |
| dc.subject | idraparinux | en_US |
| dc.subject | knee replacement | en_US |
| dc.subject | liver disease | en_US |
| dc.subject | low molecular weight heparin | en_US |
| dc.subject | skin necrosis | en_US |
| dc.title | Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair | en_US |
| dc.type | info:eu-repo/semantics/review | |
| dc.identifier.doi | https://doi.org/10.1002/14651858.CD011762 | |
| dc.subject.ocde | https://purl.org/pe-repo/ocde/ford#3.01.05 | |
| dc.relation.issn | 1469-493X |
Ficheros en el ítem
| Ficheros | Tamaño | Formato | Ver |
|---|---|---|---|
|
No hay ficheros asociados a este ítem. |
|||
Este ítem aparece en la(s) siguiente(s) colección(ones)
-
Artículos en revistas indizadas [4988]
Recuperados de bases de datos bibliográficas
Excepto si se señala otra cosa, la licencia del ítem se describe como info:eu-repo/semantics/restrictedAccess
